← Back
NeuroTrials.ai
Neurology Clinical Trial Database

NR-aMCI Pilot

A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment

Year of Publication: 2026

Authors: Martens CR, Decker KP, DeConne TM, et al.

Journal: Alzheimer's & Dementia

Citation: Alzheimers Dement 2026;22(7):e71605

Link: https://doi.org/10.1002/alz.71605

Bottom Line

In this single-center phase-II pilot RCT of 42 completers, nicotinamide riboside safely doubled blood NAD+ but did not improve cognitive function, total cerebral blood flow, blood pressure, or arterial stiffness at 12 weeks; exploratory analyses suggested regional increases in hippocampal perfusion that require confirmation in larger trials.

Major Points

  • Single-center, double-blind, placebo-controlled parallel-arm phase-II pilot trial at the University of Delaware (NCT03482167).
  • Enrolled community-dwelling older adults (≥65 y) with amnestic MCI by NIA-AA/Petersen criteria; 52 randomized (stratified by sex and APOE), 42 completed (NR n=22, placebo n=20).
  • Intervention: nicotinamide riboside 500 mg BID (1000 mg/day) vs matching microcrystalline-cellulose placebo × 12 weeks; conducted under an FDA IND.
  • NAD+ pharmacodynamic engagement confirmed — blood NAD+ ~doubled with NR (24.1→48.5 µM) vs no change with placebo (p<0.001; d=1.88).
  • Primary outcome (cognitive composite: CVLT-III, WMS-IV Logical Memory/Visual Reproduction, NIH Toolbox Fluid Cognition): no significant group×time interaction on any measure; largest effect on WMS-IV Logical Memory II (d=0.607, p=0.062).
  • Secondary outcomes (total CBF, SBP, DBP, PWV, carotid compliance): all non-significant. Total CBF p=0.135; DBP p=0.052; PWV p=0.552.
  • Exploratory: left hippocampal CBF increased significantly with NR (p=0.033; d=0.736); aortic augmentation index decreased (p=0.054; d=0.628); no correction for multiple comparisons.
  • Safety: no serious adverse events in either group; adherence 85±5% NR vs 91±1% placebo (p=0.22); mild GI symptoms and headaches in NR arm; 4 discontinued due to AEs (3 placebo, 1 NR).
  • Baseline plasma biomarkers: pTau-217 positivity only in ~32% (single-cutoff), suggesting many participants lacked biological AD — a source of heterogeneity that likely limited detection of cognitive effects.

Design

Study Type: Randomized Controlled Trial (Phase II, single-center, placebo-controlled, parallel-arm pilot)

Randomization: 1

Blinding: Double-blind — participants, investigators, and biostatisticians blinded; coordinators had only blinded group labels (A/B) for capsule preparation. Allocation stratified by sex and APOE genotype using REDCap.

Enrollment Period: March 20, 2019 – August 21, 2023 (paused during COVID-19 in March 2020)

Follow-up Duration: 12 weeks

Centers: 1

Countries: USA

Sample Size: 52

Analysis: Completer analysis using generalized linear mixed-effects models with treatment-by-time interaction; effect sizes derived from generalized f² converted to Cohen's d; α=0.05, two-sided; no correction for multiple comparisons (pilot). Covariates not included due to small sample.


Inclusion Criteria

  • Community-dwelling adults aged ≥65 years
  • Self-reported memory complaint (via targeted mailings and social media)
  • Modified Telephone Interview for Cognitive Status (TICS-m) 21–34 or delayed recall ≤10 at telephone screen
  • Amnestic MCI classification per 2011 NIA-AA workgroup and Petersen criteria: objective memory ≥1.5 SD below age-adjusted norms on HVLT-R plus BVMT-R or WMS-IV Logical Memory
  • CDR global score <1.0 (i.e., absence of dementia)
  • Written informed consent

Exclusion Criteria

  • Abnormal liver enzymes or eGFR <30 mL/min/1.73 m²
  • Any current systemic illness other than diabetes
  • History of cancer other than basal cell carcinoma (added by DSMB after study initiation)
  • Major psychiatric disorder (schizophrenia, bipolar, major depression within past 2 years)
  • Neurologic/autoimmune conditions affecting cognition (Parkinson's disease, epilepsy, multiple sclerosis, TBI, large-vessel infarct)
  • Concussion within past 2 years or ≥3 lifetime concussions
  • Substance use disorder or current smoking (including marijuana) within past 3 months
  • Use of medications that affect cognition (e.g., anticholinergics, long-acting benzodiazepines)
  • Prior hospitalization for COVID-19
  • History of cardiac arrhythmias or palpitations
  • MRI contraindications (excluded only from MRI portion, not entire study)

Baseline Characteristics

CharacteristicPlacebo (n=25)NR (n=24)
Mean Age (yrs)71 ± 772 ± 8
Sex - Female72%54%
Race - White64%92%
Race - Black28%4%
Race - Asian8%
Hispanic or Latino4%4%
APOE ε4 carrier40%42%
MMSE (raw)27 ± 226 ± 2
CDR global0.4 ± 0.20.4 ± 0.2
HVLT T-score39 ± 838 ± 8
WMS Logical Memory delayed (scaled)8 ± 38 ± 3
Right hippocampal volume (mm³)3597 ± 1313823 ± 110
Left hippocampal volume (mm³)3467 ± 1093674 ± 106
WMH volume (cm³)9.7 ± 1.511 ± 1.6
Plasma pTau-217 (pg/mL)0.38 ± 0.0660.33 ± 0.049
pTau-217 positivity (>0.42)39%26%
Plasma Aβ42/400.060 ± 0.0030.066 ± 0.005
Plasma NfL (pg/mL)21.2 ± 1.820.9 ± 1.9
Plasma GFAP (pg/mL)167 ± 21170 ± 15
Race - More than one4%

Arms

FieldNicotinamide Riboside (NR)Control
InterventionOral NR 500 mg twice daily (1000 mg/day total) as two 250-mg capsules AM and two 250-mg capsules PM (Niagen Biosciences / ChromaDex, under an FDA IND).Matching microcrystalline-cellulose capsules, identical in size and color, four capsules daily (two AM, two PM).
Duration12 weeks12 weeks

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Change in cognitive function from baseline to week 12, measured by California Verbal Learning Test-III (CVLT-III), Wechsler Memory Scale-IV Logical Memory and Visual Reproduction subtests, and NIH Toolbox v2.0 Fluid Cognition Composite. Analyzed via generalized linear mixed model treatment×time interaction.PrimaryCVLT-III Trials 1–5: Placebo 39→42 vs NR 40→41; p=0.426; d=0.21 · CVLT-III Delayed recall: Placebo 7→8 vs NR 7→9; p=0.836; d=0.07 · CVLT-III Discriminability: Placebo 83→82 vs NR 83→84; p=0.562; d=0.19 · WMS-IV Logical Memory I: Placebo 18→21 vs NR 20→25; p=0.322; d=0.32 · WMS-IV Logical Memory II (delayed): Placebo 15→16 vs NR 15→19; p=0.062; d=0.607 (largest effect, non-significant) · WMS-IV Logical recognition: Placebo 23→23 vs NR 22→24; p=0.243; d=0.38 · WMS-IV Visual Reproduction I: Placebo 29→30 vs NR 29→30; p=0.850; d=0.06 · WMS-IV Visual Reproduction II: Placebo 17→19 vs NR 17→18; p=0.396; d=0.27 · WMS-IV Visual recognition: Placebo 5→6 vs NR 5→5; p=0.118; d=0.51 · NIH Toolbox Fluid Cognition: Placebo 87→89 vs NR 84→84; p=0.398; d=0.27
Total cerebral blood flow (mL/min/100 g)Secondary0.135
Systolic blood pressure (mmHg)Secondary0.187
Diastolic blood pressure (mmHg)Secondary0.052
Pulse-wave velocity (cm/s)Secondary0.552
Carotid complianceSecondary0.505
Total NAD+ metabolome (µM)Secondary<0.001
Blood NAD+ (µM)Secondary<0.001
Blood NADH (µM)Secondary0.022
Exploratory: Left hippocampal CBFSecondary0.033
Exploratory: Total hippocampal CBFSecondary0.050
Exploratory: Aortic augmentation index (%)Secondary0.054
Exploratory: Posterior cingulate CBFSecondary0.057
Exploratory: Total DMN CBFSecondary0.079
Serious adverse eventsAdverseNone in either group
Overall AE incidenceAdverseNot significantly different between NR and placebo
Most common AEs (NR)AdverseMild transient GI symptoms (nausea, diarrhea) and mild headaches
AdherenceAdverseNR 85 ± 5%; Placebo 91 ± 1%; p=0.22
Discontinuations for AEsAdverse4 total — 3 placebo (flatulence + sleep disturbance, heart palpitations, chest pain) and 1 NR (low eGFR)
Clinical labsAdverseSmall statistically significant time×group changes in ALT, relative monocytes, and MCV — not clinically meaningful; all other labs stable

Subgroup Analysis

Study underpowered for stratified analyses; authors noted qualitatively that individuals with lower baseline CBF appeared to have larger CBF gains with NR, but no formal subgroup significance tests were conducted. Prespecified stratification variables (sex, APOE) not analyzed as effect-modifiers.


Criticisms

  • Small pilot sample (52 randomized, 42 completers) with wide confidence intervals — clearly underpowered to detect cognitive effects.
  • Completer analysis rather than intention-to-treat; excluded 3 pre-randomization withdrawals and treats missing data as MAR.
  • No adjustment for multiple comparisons across dozens of cognitive, CBF, biomarker, and vascular outcomes — inflates false-positive risk for exploratory left-hippocampal CBF and aortic AIx findings.
  • Enrollment based on behavioral criteria for aMCI rather than biomarker-defined AD; only ~32% of participants were pTau-217 positive, so the majority may not have had underlying AD pathology, diluting any disease-modifying signal.
  • Racial imbalance (Black/African American: 28% placebo vs 4% NR), which may confound cerebrovascular findings.
  • 12-week treatment duration likely too short to detect meaningful cognitive change or effects mediated by slow brain NAD+ uptake.
  • Single-center trial at one U.S. site; generalizability limited.
  • COVID-19 pandemic caused protocol changes (BVMT-R replaced with WMS-IV Logical Memory for screening; some tests conducted virtually), producing measurement heterogeneity.
  • Sample size was originally powered for vascular endpoints (BP, arterial stiffness) rather than for cognition, so the null cognitive result is expected rather than definitive.

Funding

NIH/National Institute on Aging Career Development Award K01AG054731 (PI: Martens); NIH/NIGMS Institutional Development Award P20GM113125. Nicotinamide riboside and placebo capsules provided by Niagen Biosciences (formerly ChromaDex) under a Material Transfer Agreement; the company had no other involvement.

Based on: NR-aMCI Pilot (Alzheimer's & Dementia, 2026)

Authors: Martens CR, Decker KP, DeConne TM, et al.

Citation: Alzheimers Dement 2026;22(7):e71605

Content summarized and formatted by NeuroTrials.ai.